Contributions
Abstract: P650
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Background: Oral disease modifying treatments (DMT) take a growing place among MS treatments, but no clear data are available regarding indications in a real-life setting. Knowledges concerning patients" satisfaction about these new DMTs are also scarce.
Goals: To provide data concerning patients receiving teriflunomide or dimethylfumarate (DMF) in an unselected population of patients in France, with a special focus on patients" satisfaction.
Methods: Cross sectional study conducted from January to March 2015 for the DMF (available in France 05/2014) cohort and from January to March 2016 for the teriflunomide (available in France 11/2014) cohort. All the patients treated in Auvergne, an administrative area in the centre of France, have been included thanks to the collaboration of all the neurologists working both in liberal or hospital settings. The patients completed a self-administered postal survey corresponding to the Treatment Satisfaction Questionnaire for Medication (TSQM).
Results: 146 patients receiving teriflunomide (46±11 years old; 86% women; EDSS = 2.1±1.7) and 161 receiving DMF (46±12 years old; 78% women; EDSS = 1.9±1.6) have been included. Patients receiveing DMF had a slightly higher annualised relapse rate at treatment initiation (0.6±0.7 vs 0.4±0.7; p=0.01). Concerning teriflunomide, one third of the patients had never received any DMT before and the median follow-up was 6 months. For those receiving DMF, 24% had received this treatment as a first DMT and the median follow-up was 5 months. At the time of the survey, 10% and 19% had discontinued teriflunomide and DMF, respectively (p=0.04). Detailed results from the TSQM will be presented.
Conclusions: Teriflunomide and DMF were prescribed to the same type of patients in a real life setting. Both treatments were appreciated by the patients, but the discontinuation rate was slightly more important for patients receiving DMF.
Disclosure:
Moisset: non-financial support from Merck-Serono, Biogen, Sanofi-Pasteur-MSD, Roche, GSK, Astrazeneca, Novartis, Pfizer, Teva and Genzyme, personal fees from Astellas and from Institut UPSA de la douleur
Zuel: non-financial support from Genzyme and Novartis
Conde: non-financial support from Lundbeck, Biogen, Genzyme, Bayer, Aguettant, Astrazeneca, Allergan, LFB, GSK and Novartis
Pereira: Nothing to disclose
Taithe: non-financial support from Biogen, Bayer, Merck Serono, Teva, Novartis, LFB and Genzyme.
Lauxerois: non-financial support from Teva, UCB, and Eisai.
Colamarino: non-financial support from Novartis, Genzyme, Teva, Bayer, Biogen, Merck Serono, Lundbeck, Astellas, Abbott, Mundipharma, Impeto medical, Almirall, Pfizer and Grünenthal.
Clavelou: personal fees from Teva-Pharma, Merck-Serono, Novartis, Biogen, Genzyme, Bayer, Roche and Almirall
Abstract: P650
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Background: Oral disease modifying treatments (DMT) take a growing place among MS treatments, but no clear data are available regarding indications in a real-life setting. Knowledges concerning patients" satisfaction about these new DMTs are also scarce.
Goals: To provide data concerning patients receiving teriflunomide or dimethylfumarate (DMF) in an unselected population of patients in France, with a special focus on patients" satisfaction.
Methods: Cross sectional study conducted from January to March 2015 for the DMF (available in France 05/2014) cohort and from January to March 2016 for the teriflunomide (available in France 11/2014) cohort. All the patients treated in Auvergne, an administrative area in the centre of France, have been included thanks to the collaboration of all the neurologists working both in liberal or hospital settings. The patients completed a self-administered postal survey corresponding to the Treatment Satisfaction Questionnaire for Medication (TSQM).
Results: 146 patients receiving teriflunomide (46±11 years old; 86% women; EDSS = 2.1±1.7) and 161 receiving DMF (46±12 years old; 78% women; EDSS = 1.9±1.6) have been included. Patients receiveing DMF had a slightly higher annualised relapse rate at treatment initiation (0.6±0.7 vs 0.4±0.7; p=0.01). Concerning teriflunomide, one third of the patients had never received any DMT before and the median follow-up was 6 months. For those receiving DMF, 24% had received this treatment as a first DMT and the median follow-up was 5 months. At the time of the survey, 10% and 19% had discontinued teriflunomide and DMF, respectively (p=0.04). Detailed results from the TSQM will be presented.
Conclusions: Teriflunomide and DMF were prescribed to the same type of patients in a real life setting. Both treatments were appreciated by the patients, but the discontinuation rate was slightly more important for patients receiving DMF.
Disclosure:
Moisset: non-financial support from Merck-Serono, Biogen, Sanofi-Pasteur-MSD, Roche, GSK, Astrazeneca, Novartis, Pfizer, Teva and Genzyme, personal fees from Astellas and from Institut UPSA de la douleur
Zuel: non-financial support from Genzyme and Novartis
Conde: non-financial support from Lundbeck, Biogen, Genzyme, Bayer, Aguettant, Astrazeneca, Allergan, LFB, GSK and Novartis
Pereira: Nothing to disclose
Taithe: non-financial support from Biogen, Bayer, Merck Serono, Teva, Novartis, LFB and Genzyme.
Lauxerois: non-financial support from Teva, UCB, and Eisai.
Colamarino: non-financial support from Novartis, Genzyme, Teva, Bayer, Biogen, Merck Serono, Lundbeck, Astellas, Abbott, Mundipharma, Impeto medical, Almirall, Pfizer and Grünenthal.
Clavelou: personal fees from Teva-Pharma, Merck-Serono, Novartis, Biogen, Genzyme, Bayer, Roche and Almirall